drug

NBI-1117567

1 story · latest Sep 22, 2026

Status: Investigational
Trials: 1 registered trial in coverage

Relationships

Developed by Neurocrine Biosciences

Timeline

Neurocrine registers Phase 2a trial of NBI-1117567 in mild to moderate Alzheimer's disease

Sep 22Trial updateNBI-1117567 Neurocrine Biosciences

Biotech intelligence from primary sources. Every story is an original summary of a public record, linked to its source. Not investment advice.

Terms Privacy hello@readthrough.news

readthrough is a product of JAMN Ventures, LLC.